Sweden
Medifactia is a Swedish startup in the Health Care, Manufacturing, and Medical Devices industries, founded in 2013. The company's slogan, "Transit-Pellets radiopaque markers," aligns with its focus on providing solutions for patients presenting symptoms related to constipation, diarrhea, or IBS. Medifactia's flagship product, Transit-Pellets radiopaque markers, is prescribed to evaluate the transit time and the speed of food/stool through the intestines.
For patients to undergo the Transit-Pellets test, a referral from a primary care physician or specialists is required, and the capsules can be obtained from various locations. An essential aspect of the diagnostic procedure includes an X-ray on day seven. The results generated from this test assist physicians in quantifying the severity of transit problems and guide them in determining the need for additional diagnostic procedures or selecting the appropriate therapy.
Currently, there is no available information on the last investment and the investors involved with Medifactia. This indicates that the company may either be self-funded or is not publicly disclosing its investment activities. Despite this, the company's focus on innovative medical devices and its commitment to addressing gastrointestinal health issues positions it as an interesting prospect for potential investors looking into the healthcare and medical technology sectors. With the ongoing global emphasis on healthcare innovation, Medifactia may attract significant attention and potential investment in the foreseeable future.
